AVITA Medical's SEC filings document its therapeutic acute wound-care business, RECELL-related commercial activity, operating results, capital structure, and corporate governance. Form 8-K reports include quarterly and annual financial results, material definitive agreements, credit-facility amendments and refinancing activity, leadership appointments, and board-structure changes.
Proxy materials describe annual meeting matters such as director elections, auditor ratification, non-executive director compensation, equity-award approvals, and governance requirements tied to the company's U.S. listing and ASX-related matters. The filings also provide formal disclosure around debt obligations, subsidiary guarantees, shareholder voting items, executive compensation arrangements, and risk areas affecting AVITA Medical's wound-care operations.
AVITA Medical, Inc. appointed longtime healthcare executive Cary Vance as President and Chief Executive Officer, effective April 30, 2026, after serving as Interim CEO since October 2025. He remains on the Board as an executive director, while Jan Stern Reed has been elected Chair of the Board.
Under a new employment agreement, Mr. Vance receives a base salary of $702,000, an annual bonus target of 80% of salary, and equity awards with cash values of $2,529,000 and $825,000, subject to shareholder approval at the 2027 Annual Meeting. The equity vests over three years in equal annual installments.
If the company terminates him without cause or he resigns for good reason, Mr. Vance is eligible for severance equal to a prorated annual bonus, 18 months of base salary, and 18 months of COBRA premium reimbursement, conditioned on signing a release. The company also confirmed these governance changes in an accompanying press release.
AVITA Medical, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 3, 2026. Investors will elect seven directors, ratify Grant Thornton LLP as auditor for 2026, and increase the non-executive director cash fee pool from US$750,000 to US$900,000.
Stockholders are also asked to approve multiple grants of restricted stock units and options to non-executive directors, advisory votes on executive pay and its frequency, issuance of warrants covering up to 650,000 shares to Perceptive Credit Holdings V, LP, and authority to issue additional equity securities up to 10% of issued capital under ASX rules.
AVITA Medical, Inc. filed a shelf registration statement to offer up to $200,000,000 of common stock, preferred stock, warrants and units under a Form S-3 shelf prospectus dated March 31, 2026. The prospectus states that specific terms for each offering will be set forth in a prospectus supplement. The company's common stock trades on Nasdaq under the symbol RCEL; the prospectus notes a Nasdaq closing price of $3.63 per share as of March 30, 2026. The prospectus says proceeds are expected to be used for general corporate purposes, including capital expenditures and working capital, with precise uses to be specified in future prospectus supplements.
AVITA Medical, Inc. director Woody Joseph Fralin filed an initial statement of beneficial ownership on Form 3. The filing identifies him as a director of the company and reports no buy, sell, acquire, or dispose transactions in AVITA Medical, Inc. securities.
AVITA Medical, Inc. Chief Financial Officer David D. O'Toole reported an open-market purchase of 3,000 shares of common stock on February 19, 2026 at $4.15 per share. Following this buy, his directly held stake increased to 140,127 shares, which includes unvested restricted stock units.
AVITA Medical, Inc. CFO David D. O'Toole reported equity compensation awards consisting of stock options and restricted stock units. He acquired 155,510 stock options with an exercise right to buy common shares, and 105,470 shares of common stock in the form of restricted stock units, both at a stated price of $0.00 per share.
The RSUs represent rights to receive one share of common stock each, vesting in three equal annual installments starting 12 months after the February 18, 2026 grant date. The stock options also vest in three equal annual installments beginning on the first anniversary of the same grant date, aligning his compensation with longer-term company performance.
AVITA Medical, Inc. reported that Chief Legal Officer Nicole Kelsey received equity awards consisting of stock options and restricted stock units. She was granted stock options for 145,060 shares at an exercise price of $0.0000 per share and 98,390 shares of Common Stock through restricted stock units.
The restricted stock units each represent the right to receive one share of Common Stock and vest in three equal annual installments beginning 12 months after the February 18, 2026 grant date. The stock options vest in three equal annual installments beginning on the first anniversary of the February 18, 2026 grant date, aligning the awards with multi-year service and performance.
AVITA Medical, Inc. reports in its annual filing that it remains a high-growth, loss-making acute wound care company built around its RECELL autologous cell harvesting platform and new products Cohealyx and PermeaDerm.
The company posted a net loss of $48.6 million in 2025 and has an accumulated deficit of $408.4 million, while targeting long-term profitability through broader use of RECELL in burns, traumatic and surgical wounds and international expansion. AVITA added a new senior secured credit facility of up to $60 million, drawing $50 million and using part of the proceeds to refinance prior debt. It emphasizes extensive FDA approvals, growing clinical and health-economic evidence, and a sizable patent and trademark portfolio as competitive strengths, but warns that execution, reimbursement, regulatory, manufacturing, cybersecurity, and high leverage risks could materially affect results.
AVITA Medical reported fourth quarter 2025 revenue of $17.6 million, down slightly from $18.4 million a year earlier, as reimbursement headwinds continued to weigh on sales. Gross margin was 81.2%, below the prior year, but operating expenses fell to $24.7 million, helping keep the quarterly net loss flat at $11.6 million.
For full-year 2025, revenue grew about 11% to $71.6 million, while the net loss narrowed to $48.6 million from $61.8 million as the company cut sales, marketing, and administrative costs. AVITA ended 2025 with $18.2 million in cash and marketable securities and subsequently closed a five-year credit facility of up to $60 million, using initial proceeds to refinance debt. For 2026, it expects revenue of $80–$85 million, roughly 12–19% growth, supported by improved Medicare payment rates and advancing clinical studies.
The Vanguard Group filed an amended Schedule 13G reporting its beneficial ownership of Avita Medical Inc common stock. Vanguard reports beneficially owning 1,444,579 shares, representing 4.73% of the outstanding common stock, with shared voting power over 190,616 shares and shared dispositive power over all 1,444,579 shares.
Vanguard indicates it holds the securities in the ordinary course of business and not to change or influence control of Avita Medical. The filing notes an internal realignment on January 12, 2026, after which certain Vanguard subsidiaries or business divisions are expected to report beneficial ownership separately.